Sanofi-Aventis SA - Fighting Cancer

PARIS (Reuters) - Sanofi-Aventis' cabazitaxel candidate prostate cancer drug combined with prednisone reduced the risk of death by 28 percent compared with another treatment, the outcome of a final-stage trial showed. The French drugmaker said on Thursday that the combination of the ...

Experimental drug modestly boosts survival in men with advanced prostate cancer, study findsFor the first time, an experimental drug has extended the lives of men with advanced prostate cancer who are no longer responding to other treatments and are out of options ...

LOS ANGELES (Reuters) - U.S. officials approved a new Sanofi-Aventis drug to help fight a serious complication of cancer treatment, the company said on Friday. The Food and Drug Administration approved the drug, Elitek, for managing levels of plasma uric acid (PUA) ...

LONDON (Reuters) - Sanofi-Aventis may have bagged a winning cancer drug when it agreed to buy privately held BiPar Sciences for up to $500 million in April, but a short patent could limit the French group's scope to cash in on sales. ...

Topic: Sanofi-Aventis SA

Sanofi prostate cancer drug shows 28 percent survival

Sanofi drug shows promise against prostate cancer

U.S. clears Sanofi drug for cancer complication

Sanofi has winning cancer drug, but short patent

From Around the Web

Video Gallery

Follow this Topic with...